Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.43 |
| ▸ | MTOR | P42345 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KIF5B | P33176 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755874 | 0.86 | PIK3CA (0.45) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL752861 | 0.86 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL753370 | 0.83 | PIK3CA (0.41) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL11892542 | 0.72 | TSHR (0.37) | — | |
| SCHEMBL755689 | 0.72 | PIK3CA (0.57) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL169243 | 0.72 | PIK3CA (0.74) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL168342 | 0.71 | PIK3CA (0.75) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL754800 | 0.69 | PIK3CA (0.43) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL761257 | 0.68 | PIK3CA (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL11030618 | 0.65 | MAPKAPK2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885PIK3CD 3/4885PIK3CB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.